These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31952494)

  • 1. "A very humiliating illness": a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa.
    Furin J; Loveday M; Hlangu S; Dickson-Hall L; le Roux S; Nicol M; Cox H
    BMC Public Health; 2020 Jan; 20(1):76. PubMed ID: 31952494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Take the treatment and be brave": Care experiences of pregnant women with rifampicin-resistant tuberculosis.
    Loveday M; Hlangu S; Furin J
    PLoS One; 2020; 15(12):e0242604. PubMed ID: 33347448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "This is not my body": Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosis.
    Loveday M; Hlangu S; Larkan LM; Cox H; Daniels J; Mohr-Holland E; Furin J
    PLoS One; 2021; 16(10):e0251482. PubMed ID: 34662887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Life continues": Patient, health care and community care workers perspectives on self-administered treatment for rifampicin-resistant tuberculosis in Khayelitsha, South Africa.
    Mohr E; Snyman L; Mbakaz Z; Caldwell J; DeAzevedo V; Kock Y; Trivino Duran L; Venables E
    PLoS One; 2018; 13(9):e0203888. PubMed ID: 30216368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.
    Cox H; Ramma L; Wilkinson L; Azevedo V; Sinanovic E
    Trop Med Int Health; 2015 Oct; 20(10):1337-45. PubMed ID: 25975868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
    Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
    BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic needs and challenges of people with drug-resistant tuberculosis and HIV in South Africa: a qualitative study.
    Daftary A; Mondal S; Zelnick J; Friedland G; Seepamore B; Boodhram R; Amico KR; Padayatchi N; O'Donnell MR
    Lancet Glob Health; 2021 Apr; 9(4):e479-e488. PubMed ID: 33740409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organisation of care for people receiving drug-resistant tuberculosis treatment in South Africa: a mixed methods study.
    Dickson L; Le Roux SR; Mitrani L; Hill J; Jassat W; Cox H; Mlisana K; Black J; Loveday M; Grant A; Kielmann K; Ndjeka N; Moshabela M; Nicol M
    BMJ Open; 2023 Nov; 13(11):e067121. PubMed ID: 37977868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What clinic closure reveals about care for drug-resistant TB: a qualitative study.
    Govender T; Furin JJ; Edwards A; Pillay S; Murphy RA
    BMC Infect Dis; 2023 Jul; 23(1):474. PubMed ID: 37460960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
    Cox H; Dickson-Hall L; Ndjeka N; Van't Hoog A; Grant A; Cobelens F; Stevens W; Nicol M
    PLoS Med; 2017 Feb; 14(2):e1002238. PubMed ID: 28222095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparing the healthcare workforce in South Africa for short-course rifampicin-resistant TB treatment: inter-professional training and task-sharing considerations.
    Farley JE; Ndjeka N; Mlandu K; Lowensen K; Geiger K; Nguyen Y; Budhathoki C; Stamper PD
    Hum Resour Health; 2021 Jan; 19(1):6. PubMed ID: 33407541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.
    Evans D; Schnippel K; Govathson C; Sineke T; Black A; Long L; Berhanu R; Rosen S
    PLoS One; 2017; 12(7):e0181238. PubMed ID: 28746344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving outcomes for multi-drug-resistant tuberculosis in the Peruvian Amazon - a qualitative study exploring the experiences and perceptions of patients and healthcare professionals.
    McNally TW; de Wildt G; Meza G; Wiskin CMD
    BMC Health Serv Res; 2019 Aug; 19(1):594. PubMed ID: 31438958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Person-centred care and short oral treatment for rifampicin-resistant tuberculosis improve retention in care in Kandahar, Afghanistan.
    Mesic A; Ishaq S; Khan WH; Mureed A; Mar HT; Khaing EE; Bermudez-Aza E; Rose L; Lynen L; Seddiq MK; Amirzada HK; Keus K; Decroo T
    Trop Med Int Health; 2022 Feb; 27(2):207-215. PubMed ID: 34978748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients' experiences in the era of rapid molecular diagnostic tests.
    Naidoo P; van Niekerk M; du Toit E; Beyers N; Leon N
    BMC Health Serv Res; 2015 Oct; 15():488. PubMed ID: 26511931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of a psychosocial support package for people receiving treatment for multidrug-resistant tuberculosis in Nepal: A feasibility and acceptability study.
    Walker IF; Khanal S; Hicks JP; Lamichhane B; Thapa A; Elsey H; Baral SC; Newell JN
    PLoS One; 2018; 13(7):e0201163. PubMed ID: 30048495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health care workers' fears associated with working in multidrug- and or extensively-resistant tuberculosis wards in South Africa.
    Tudor C; Mphahlele M; Van der Walt M; Farley JE
    Int J Tuberc Lung Dis; 2013 Oct; 17(10 Suppl 1):22-29. PubMed ID: 24020597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa.
    Sineke T; Evans D; Schnippel K; van Aswegen H; Berhanu R; Musakwa N; Lönnmark E; Long L; Rosen S
    Health Qual Life Outcomes; 2019 May; 17(1):94. PubMed ID: 31151398
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.